Novel molecular-targeted agents for GIST (Regorafenib etc.)
Naito, Y.; Doi, T.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 40(1): 15-18
2013
ISSN/ISBN: 0385-0684 PMID: 23306914 Document Number: 671285
Gastrointestinal stromal tumors(GIST)are the most frequent sarcoma arising from gastrointestinal tract. Imatinib and sunitinib are proven to be efficacious against GIST and become standard of care. Moreover several novel molecular-targeted agents are in development. Regorafenib significantly improved progression-free survival in patients with GIST who were treated with imatinib and sunitinib in a randomized phase III trial and is considered a new standard option.